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NK cells represent an important first line of defense against viral infection and cancer and 
are also involved in tissue homeostasis. Studies of NK cell activation in the last decade 
have revealed that they are able to respond to the inflammatory stimuli evoked by tissue 
damage and contribute to both progression and resolution of diseases. Exacerbation of 
the inflammatory response through interactions between immune effector cells facilitates 
the progression of non-alcoholic fatty liver disease (NAFLD) into steatosis, cirrhosis, 
and hepatocellular carcinoma (HCC). When hepatic damage is incurred, macrophage 
activation is crucial for initiating cross talk with neighboring cells present in the liver, 
including hepatocytes and NK cells, and the importance of this interaction in shaping the 
immune response in liver disease is increasingly recognized. Inflicted structural damage 
can be in part regenerated via the process of self-limiting fibrosis, though persistent 
hepatic damage will lead to chronic fibrosis and loss of tissue organization and function. 
The cytotoxic activity of NK cells plays an important role in inducing hepatic stellate cell 
apoptosis and thus curtailing the progression of fibrosis. Alternatively, in some diseases, 
such as HCC, NK cells may become dysregulated, promoting an immunosuppressive 
state where tumors are able to escape immune surveillance. This review describes 
the current understanding of the contributions of NK cells to tissue inflammation and 
metabolic liver diseases and the ongoing effort to develop therapeutics that target the 
immunoregulatory function of NK cells.
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iNTRODUCTiON
The liver plays a critical role in functioning as both a metabolic and immunological site. It receives 
a dual blood supply; one-quarter is oxygen-rich blood delivered by the hepatic artery, while the 
remaining three-quarters is blood draining from the gastrointestinal tract and spleen via the portal 
vein, enriched in dietary- and environmental-antigen (1). Liver sinusoidal endothelial cells (LSECs) 
form the walls of hepatic sinusoids and present numerous fenestrations, allowing blood to contact 
the underlying hepatocytes. Slow blood flow in hepatic sinusoids allows a better interaction between 
circulating lymphocytes, liver sinusoidal endothelium, and hepatocytes to facilitate the clearance of 
gut-derived antigens by liver-resident cells (2). To compensate for the high exposure to circulating 
antigens, the liver must maintain a tolerant microenvironment in which there is constant low-level 
suppression of immune responses. Liver immune cells are educated to permit immunological toler-
ance to self-antigens, environmental, and dietary antigens, during homeostasis, but can initiate both 
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innate and adaptive immune responses in the context of infection 
(3). In humans and mice, the liver is largely composed of hepato-
cytes (80% of the liver mass), while the remaining 20% is made up 
of non-parenchymal cells including lymphocytes, myeloid cells, 
Kupffer cells (liver-resident macrophages, KCs), HSCs, and LSECs 
(4, 5). NK cells are enriched in the liver, representing 25–30% of 
human liver lymphocytes compared to 10–20% of total periph-
eral blood mononuclear cell (PBMC) lymphocytes (6). However, 
during chronic hepatitis B and C, NK cell numbers are increased 
through recruitment by KC-secreted chemokines (7, 8), and the 
survival of NK  cells is enhanced by cytokine production from 
Kupffer cells, LSECs, and T  cells (9). The high immunological 
load present during infection, a large proportion of which are 
NK cells, results in a unique immune environment.
NK cells are widely distributed in both lymphoid (bone marrow 
and liver) and non-lymphoid organs (peripheral blood, lung, and 
uterus) and bridge the gap between innate and adaptive immune 
responses. They conduct immunosurveillance by probing cells 
via their inhibitory receptors [NKG2A and the Ly-49 family 
in mice, and killer-immunoglobulin-like receptor (KIR) and 
NKG2A in humans] to determine whether the correct self major 
histocompatibility complex (MHC) is expressed and to ensure 
tolerance against healthy cells. In humans and mice, NK cells can 
detect infected, transformed, or stressed cells with their activat-
ing receptors (NKG2D and NKp46), resulting in their activa-
tion. NK cell activation can be triggered many ways, including 
cross-linking of activating receptors (NKG2D and NKp46) with 
simultaneous disengagement of inhibitory receptors (NKG2A) or 
by various cytokines such as type I IFNs, IL-2, IL-12, IL-15, and 
IL-18. Additionally, NK  cells can be directly activated through 
CD16A signaling that triggers antibody-dependent cell-mediated 
cytotoxicity (ADCC) or receive signals through toll-like receptors 
(TLRs) expressed on their surface, which recognize pathogen-
associated molecular patterns (PAMPs) expressed by injured cells 
(10). Upon activation, NK cells can become cytotoxic and release 
lytic granules (perforin, granzymes) or induce death signals 
through expression of death receptors (TRAIL/TRAIL-R, FasL/
Fas) (11, 12). While NK cells are able to mediate their functions 
in an antigen-independent, innate manner, recent investigations 
have suggested that liver-resident NK cells are capable of acquiring 
antigen-specific memory. In studies that utilized murine models, 
it was shown that a persistent and transferable NK cell memory 
response is generated to haptens and viruses and that the reten-
tion of this memory population requires CXCR6 expression (13). 
This antigen-specific NK memory has further been studied in 
non-human primates, where it has been maintained up to 5 years 
(14). However, the underlying mechanisms for the generation of 
NK memory responses still remain to be elucidated.
The interplay between NK cells and their surrounding tissues 
and immune cells shapes NK cell maturation and function. In the 
liver, cross talk between NK cells and macrophages during various 
phases of liver injury-induced inflammation allows NK cells to 
regulate both inflammatory and anti-inflammatory macrophages 
(Figure 1). Hepatic macrophages play a central role in the patho-
genesis of chronic liver disease (15). They can exert dual responses 
depending on their origin, the phase of liver immune response, the 
developmental stage of a disease, or the acute/chronic profile of a 
disease. Macrophages can differentiate into a wide range of pro-
inflammatory/classical M1 to immunoregulatory/alternative M2 
macrophage profile under inflammatory conditions during liver 
injury (16). M1 macrophages are activated by pro-inflammatory 
cytokines (IFN-γ, IL-12, or TNF-α) and/or microbial products 
(LPS) and can phagocytose bacteria and virus, as well as release 
pro-inflammatory cytokines and chemokines. M2 macrophages 
are induced by IL-4, IL-10, and IL-13 produced by various cell 
types (16). There are several subtypes of M2 macrophages whose 
functions vary between wound healing (fibrogenic activity and 
tissue repair), restorative function (matrix resolution and tis-
sue repair), or pro-inflammatory (“turnoff immune response”) 
activity.
Moreover, NK cell function can be shaped by inflammasomes, 
which are triggered in response to cell damage. Inflammasome 
components are expressed in hepatocytes, KCs, and macrophages 
and contribute to the induction of liver inflammation via pyrop-
totic cell death and release of alarmins as well as the cleavage and 
secretion of IL-1β and IL-18. The inflammasome sensor NLRP3 
responds to extracellular ATP released from dying cells and to 
reactive oxygen species triggered by phagosome damage from 
engulfment of particulates (17, 18). Mice deficient in NLRP3 
are protected in diet-induced and some infection models of 
liver injury (19–24). Viral double-stranded DNA can trigger the 
inflammasome by binding AIM2 expressed on hepatocytes (25). 
In the case of hepatitis C virus (HCV) infection, both hepatocytes 
and KC have been shown to release IL-1β and IL-18. Notably, KCs 
appear to be responsible for activating NK cells via this mecha-
nism (25–27). While cell death and release of alarmins exacerbate 
liver inflammation, IL-18 exerts a protective function to limit liver 
injury. This may in part be due to the NK cell-mediated activation 
of other immune mediators, including the induction of PD-L1 
and FasL, as well as the essential role of cytokine in eliciting NK 
memory (28–31). These findings support the pathophysiological 
role of inflammasomes in hepatic inflammation and liver injury.
CHARACTeRiSTiCS OF LiveR NK CeLLS
Liver NK cells are a unique cell population in terms of frequency, 
phenotype, and function (32). Due to its anatomical structure, 
blood supply, immune resident cell repertoire, and the constant 
exposure to dietary- and gut-derived antigens, the tolerogenic 
liver microenvironment may be conducive for the enrichment and 
characteristics of liver NK cells (33). While the majority of NK cells 
originate in bone marrow from progenitor NK cells (NKPs), some 
NK  cells evolve in other lymphoid tissues such as the thymus 
and lymph nodes (34, 35). Compared to bone marrow-derived 
NK  cells, NK  cells developing from the thymus demonstrate a 
higher expression of GATA-3 and CD127 and require IL-7 signals 
for their development (34). The earliest committed NKPs in mouse 
bone marrow are identified as DX5−CD161−CD122+ and are 
dependent on the Id2 transcription factor (36). NKPs then acquire 
the expression of phenotypic markers NK1.1, NKp46, CD94/
NKG2 receptors, Ly49 receptors, and DX5 to become mature 
NK cells. The expression of CD11b and CD27 are used to define 
the maturation status of mouse NK cells. NK cell maturation is 
categorized into four stages based on the acquisition of CD11b 
FigURe 1 | in the context of viral infection or fatty liver disease, NK cells can be stimulated via their activating receptors or by toll-like receptors 
(TLRs) that recognize pathogen-associated molecular patterns and DAMPs expressed by injured cells. During liver injury-induced inflammation, NK cells 
are able to regulate inflammatory (M1) and anti-inflammatory (M2) macrophages depending on the phase of the immune response and stage of disease.
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expression and the loss of CD27. The most immature NK cells are 
defined as CD11b−CD27−, and these progress to CD11b−CD27+, 
then CD11b+CD27+, and finally become the most mature NK cells 
by expressing CD11b+CD27−. Mature CD11b+ CD27−NK  cells 
are predominant in the spleen, and immature CD11b−CD27+ 
NK cells are more prevalent in the liver (37).
The liver is populated by conventional NK (cNK) cells and 
resident NK cells that are distinguished by the mutually exclusive 
expression of the integrins DX5 and CD49a, respectively. Mouse 
NK cells are usually identified by the cell surface phenotype of 
CD3−DX5+. The expression of NK activating receptor, NKp46, 
is also used as a phenotypic marker in mice and humans, with 
cNK  cells defined by the phenotype of CD49a−NKp46+DX5+ 
CD3−, and liver-resident NK cells identified by CD49a+NKp46+ 
DX5−CD3−, with low expression of CD11b and Ly49, and high 
expression of TRAIL (38). During homeostasis, cNK  cells are 
highly migratory, circulating throughout the body and primarily 
found in bone marrow, blood, and spleen. Activated cNK cells 
produce a large amount of cytokines but display low cytolytic 
activity. Recently, liver-resident NK  cells have been identified 
as members of innate lymphoid cells (ILCs) and constitute the 
group 1 ILCs, along with ILC1s (39–42). Both NK cells and ILC1s 
are characterized by their expression of the transcription factor 
T-bet, but NK cells are distinctive in their expression of EOMES. 
While not in the scope of this review, there are numerous others 
that cover ILC biology, nomenclature, and the vast differences in 
transcriptional regulation, receptor expression, and localization 
that may be helpful (43–45). Liver-resident NK cells have more 
cytotoxicity, but less IFN-γ production following IL-12/IL-18 
stimulation than NK cells in the blood and spleen under homeo-
static conditions (31). In contrast, a recent report demonstrates 
that ILC1s are able to produce higher levels of cytokines (IFN-γ) 
than cNK  cells following PMA/ionomycin stimulation (46). 
Within the liver, CD49a+DX5− NK  cells are found at a signifi-
cantly higher frequency compared to other sites (bone marrow, 
spleen, blood) and selectively reside in hepatic sinusoids. Liver 
CD49a+DX5− NK  cells express high levels of TRAIL and have 
cytotoxic activity against tumor cells. TRAIL+ NK cells predomi-
nate in fetal and neonatal mice, and in adulthood are present in the 
liver, but not the spleen. Tissue-resident CD49a+DX5− NK cells 
are also found in the uterus and skin (46).
Human NK  cells are CD3−CD56+ lymphocytes and can be 
divided into two subsets based on the level of expression of 
CD56 and CD16. CD16+CD56dim NK  cells represent 90% of 
blood and spleen NK  cells and demonstrate higher cytotoxic 
activity than CD16−CD56bright NK cells by producing high levels 
of granzymes and perforin. CD16+CD56dim NK cells have high 
expression of KIR and express intermediate-affinity IL-2 recep-
tor resulting in low expansion capacity under IL-2 stimulation. 
Representing only 10% of blood NK  cells, CD16−CD56bright 
FigURe 2 | Suppression of NK cell-derived iFN-γ production is mediated by CD33+CD11bloHLA-DRlo myeloid-derived suppressor cells (MDSCs) 
following a reduction in available arginine via an Arg-1 mechanism. During HCV infection, HCV core protein induces MDSC development. Following the loss 
of arginine, the mTOR pathway is unable to efficiently translate IFN-γ mRNA, and the subsequent loss of IFN-γ protein production and secretion from NK cells in the 
liver results in immune evasion by HCV.
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NK  cells are predominant in secondary lymphoid organs such 
as lymph nodes. In the liver, both populations are present with 
the same frequency. CD16−CD56bright NK cells exhibit less cyto-
lytic activity than CD16+CD56dim NK cells but demonstrate the 
same cytotoxicity after prolonged activation. CD16−CD56bright 
NK  cells express high- and intermediate-affinity IL2-receptor 
facilitating their in vivo and in vitro expansion under low doses 
of IL-2. Additionally, they are more responsive to stimulation 
by pro-inflammatory cytokines. Upon activation, they produce 
cytokines (IFN-γ, IL-10, GM-CSF, and TNF-α) and chemokines. 
A recent study suggested that CD16−CD56bright NK  cells might 
represent liver-resident NK cells with high expression of CD69, an 
activation marker, and expression of CXCR6 and CCR5 to retain 
them in the liver (47). The development and the differentiation of 
human liver-resident NK cells are still undefined. As an antiviral 
effect, NK cells secrete granzyme B and perforin to lyse virally 
infected cells and induce their apoptosis and secrete cytokines 
such as TNF-α and IFN-γ to further the immune response (48). 
In particular, NK IFN-γ production has direct cytotoxic effects 
on virally-infected cells, elicits an antiviral state in the uninfected 
cells, and induces chemotaxis to recruit adaptive immune cells (6, 
49, 50). HCV patients with chronic infection show poor NK cell 
responses compared to patients with resolved HCV infection. The 
in vitro studies on co-cultures of NK cells with HCV-conditioned 
CD33+ PBMCs demonstrated a reduced level of IFN-γ produc-
tion but no effect on granzyme B release. This suppression of 
NK cell-derived IFN-γ production has been shown to be medi-
ated by CD33+CD11bloHLA-DRlo myeloid-derived suppressor 
cells (MDSCs) via an arginase-1-dependent inhibition of mTOR 
activation (Figure 2) (51). These results identify the induction of 
MDSCs in HCV infection as a potent immune evasion strategy 
that suppresses antiviral NK cell responses.
ROLe OF NK CeLLS iN LiveR DiSeASe
As a result of tight regulatory controls, loss of liver tissue can be 
regenerated via the process of self-limiting fibrosis (3). Indeed, 
the liver can be fully recovered structurally and functionally 
even after a loss of 50% of its hepatocytes. While fibrosis can be 
beneficial in an acute sense, repeated hepatic damages due to 
persistent inflammation or infection can lead to chronic fibrosis, 
resulting in a loss of liver tissue organization and function and 
eventually, cirrhosis (3). At this stage, if cirrhosis fails to regress 
to early stage fibrosis, there is a high risk for developing irrevers-
ible hepatocellular carcinoma (HCC). The most common causes 
of fibrosis are chronic viral infections (HBV, HCV), frequent use 
of hepatotoxic drugs (acetaminophen, ibuprofen), or metabolic 
syndromes [non-alcoholic fatty liver disease (NAFLD)] that trig-
ger chronic inflammation. Fibrosis results in activation of HSCs 
and macrophages that produce extracellular matrix (ECM), 
forming scar tissue. As a result of liver damage, dying hepatocytes 
are cleared by liver macrophages, which trigger an inflamma-
tory response by secreting cytokines and chemokines to recruit 
other cells to the wound site and initiate the process of tissue 
repair. In an inflamed hepatic microenvironment, HSCs become 
activated and differentiate into myofibroblasts that produce 
FigURe 3 | The activation stage of HSCs can influence the ability of NK cells to exert cytotoxic activity. While quiescent HSCs are resistant to apoptotic 
signals, their activation leads to increased surface expression of TRAIL-R. Following engagement of their activating receptors, NK cells can conduct cytotoxic activity 
by releasing lytic granules or by transduction of death signals through death receptor/ligand interactions (i.e., TRAIL/TRAIL-R, FasL/Fas). Fully activated HSCs 
expressing Timp-1 are protected from apoptosis. These HSCs can differentiate into myofibroblasts that produce large amounts of fibrous proteins, which can lead 
to fibrosis when not restrained. ECM, extracellular matrix.
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a large amount of fibrous proteins (collagen, elastin, laminin, 
fibronectin). The progression of fibrosis depends on the balance 
between production of ECM components and their degradation 
by metalloproteinase produced by restorative M2 macrophages. 
In this review, we will focus on the dual role of NK cells in the 
initiation, progression, and resolution of liver fibrosis and how 
it is regulated by the cross talk of NK  cells with surrounding 
macrophages and stellate cells.
Role of NK Cells in Fibrosis
NK  cells play a paradoxical role in the development of liver 
fibrosis. The cytotoxic activity of NK cells can curtail the develop-
ment of fibrosis by killing HSC-derived myofibroblasts through 
engagement of NKG2D receptor with its ligand, RAE-1 (in 
mouse) expressed by early activated HSCs (52, 53). In humans, 
NK cells preferentially kill senescent-activated HSCs expressing 
MICA following recognition by NKG2D receptor on NK  cells 
(54, 55). In addition, the expression of NKp46 ligand on human 
and mouse-activated HSCs can also trigger NK  cell-mediated 
cytotoxic activity, ameliorating liver fibrosis (56). The ability of 
NK cells to kill HSCs seems to be dependent on the activation 
stage of HSCs and expression of specific molecules; quiescent 
HSCs and activated HSCs that express Timp-1 are resistant to 
apoptotic signals (57) (Figure 3). HSCs are the most sensitive to 
NK cytotoxicity during early activation and senescence stages.
In humans and mice, IFN-γ-producing NK  cells have been 
demonstrated to negatively regulate fibrosis. In vitro and in vivo 
studies in mouse have shown an anti-fibrotic effect of NK cell-
derived IFN-γ, which induces HSC apoptosis and cell cycle arrest. 
However, clinical trials with IFN-γ proved ineffective; the anti-
fibrotic action of IFN-γ might depend on its targeted delivery 
to HSCs (58, 59). Additionally, IFN-γ-producing DX5+NKp46+ 
cNK  cells are increased during non-alcoholic steatohepatitis 
(NASH), a cause of fibrosis, and skew the polarization of acti-
vated KC and liver macrophages toward an M1 profile, rather 
than toward a fibrosis-inducing M2 macrophage profile (60). 
Furthermore, NK cells release IL-22 upon activation, which can 
be anti-fibrogenic (61–63).
While IL-22 plays a beneficial role during acute inflammatory 
events, prolonged and excessive production of IL-22 may have 
the opposite effect (62). Continuous exposure to proliferative 
and antiapoptotic signals may drive cells to change phenotype 
and become cancerous as demonstrated in IL-22 transgenic mice 
where IL-22 primes the liver to be more susceptible to tumor 
development (64). Additionally, in HBV-infected patients and 
HBV transgenic mice, IL-22 exacerbates chronic inflammation 
and the development of fibrosis by promoting Th17 cell responses 
in the liver (65–68). The dual nature of IL-22, and by extension, 
NK cells, between protection and inflammation may depend on 
the tissue and inflammatory conditions. Due to technical chal-
lenges, it is difficult to evaluate which specific NK  cell subset 
(i.e., conventional or liver-resident NK cells) has anti-fibrogenic 
effects. Most of the in vitro studies use cNK cells from human 
blood or mouse spleens and in vivo depletion experiments using 
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antibodies do not efficiently remove all liver-resident NK cells. 
Few liver-resident NK cells can be purified from a mouse liver, 
significantly prohibiting adoptive transfer.
In contrast to the anti-fibrogenic properties of some NK cells, 
other studies have demonstrated that NK cells can enhance liver 
injury by killing stressed hepatocytes via engagement of NKG2D, 
NKp30, and/or TRAIL. Additionally, they can accomplish this via 
IFN-γ-induced apoptosis, leading to the development of fibrosis 
(69–74). For example, patients with NASH show an increase in 
hepatocyte Fas expression and apoptosis, which correlates with 
the severity of the disease (75). This pathogenic role of NK cells 
has also been identified in human autoimmune liver diseases, such 
as primary biliary cirrhosis, where NK cells promote the killing of 
biliary epithelial cells via TRAIL and by releasing cytokines that 
promote adaptive immunity (76, 77). In parallel, IL-10-producing 
NK cells delay primary biliary cirrhosis by annihilating the adap-
tive immune response in killing autologous DCs and T cells (78).
Role of NK Cells in Tissue Regeneration
As many studies have now demonstrated the regulatory role of 
NK cells in fibrosis, compelling evidence also points to a role for 
NK  cells in tissue regeneration (79, 80). Hepatic NK  cells can 
interact with surrounding parenchymal and non-parenchymal 
cells to influence the release of growth hormones, cytokines, 
and chemokines within the proliferating hepatic tissues. Hepatic 
NK cells promoted liver regeneration after partial hepatectomy 
(81). NK cells may have a beneficial effect on liver tissue regen-
eration by secreting TNF-α and IL-22 during inflammation, 
which stimulate the proliferation of hepatocytes to replace dying 
hepatocytes (64, 82). NK cells might also play a role in liver regen-
eration by cross talk with hepatic macrophages known to regulate 
the differentiation of hepatic progenitor cells into hepatocytes 
(83). All of the regenerative effects of NK cells are dependent on 
optimal NK  cell activation, as overactivation actually prevents 
liver regeneration (84). Indeed, when strongly activated, NK cells 
produce excessive amounts of IFN-γ and lose self-tolerance, 
compromising liver repair (85). To maintain self-tolerance during 
regenerative hyperplasia, hepatocytes upregulate the poliovirus 
receptor (PVR/CD155) after partial hepatectomy, which engages 
the regulatory molecule T cell Ig and ITIM domain (TIGIT) on 
NK cells (84). NK cell effector functions used to resolve inflam-
mation also shape the recruitment and differentiation of stem 
cells for tissue regeneration. NK  cells enhance the recruitment 
of mesenchymal stem cells (MSCs) by producing a variety of 
chemokines, such as, NAP-2 (CXCL7), GRO-b (CXCL2), GRO-g 
(CXCL3), IL-8, and RANTES (86). MSCs have the capacity to 
differentiate into specific lineages that promote tissue repair. The 
cross talk between NK cells and MSCs has been demonstrated 
in several studies, in particular, during bone repair where 
NK cells mediate the recruitment of MSCs. Taken together, the 
dual role of NK  cells on fibrosis and tissue regeneration could 
be explained by their differentiation from actively cytotoxic cells 
to regulatory cells that produce cytokines supportive of tissue 
repair. Regulatory NK cells might be induced as a result of NK cell 
interactions with surrounding cells such as immune cells (KC and 
liver macrophages), effector cells of connective tissue (fibroblasts, 
HSCs), or stem cells.
Role of NK Cells in HCC
In mouse models of cancer and human cancer patients, NK cells 
are often dysfunctional, with reduced cytotoxic activity, impaired 
production of cytokines, and an inability to efficiently kill 
abnormal cells (87–90). In patients with HCC, there is also a 
significant reduction in both the percentage and number of total 
liver NK cells, as well as peripheral CD56dimCD16pos subsets (91, 
92). At all stages of HCC, these CD56dimCD16pos NK cells have 
a decreased ability to produce cytokine, with IFN-γ production 
following PMA/ionomycin stimulation decreasing from 50 to 
5% between healthy and HCC donors (93). Total NK cells show 
reduced production of Granzyme A, Granzyme B, and perforin 
once HCC has progressed past stage I (93). NK cells cultured with 
cancer-associated fibroblasts from HCC (H-CAFs) downregulate 
NKG2D and NKp46 and decrease expression of Granzyme B, 
perforin, TNF-α, and INF-γ (94). Following PGE2 blockade by 
the inhibitor NS398, these NK cells increased TNF-α and IFN-γ 
production, an effect that was further amplified with the addi-
tion of the indoleamine 2,3-dioxygenase (IDO) inhibitor, 1-MT 
(94). Further investigation into the interactions that contribute to 
dysregulated NK cells and by extension, the immunosuppressive 
state that facilitates HCC progression, is necessary to fully under-
stand the tumor microenvironment and how to target therapies 
to these interactions.
THeRAPeUTiCS TARgeTeD TO NK CeLLS
The immunoregulatory function of NK  cells in infection and 
inflammatory diseases makes these cells good therapeutic targets 
for controlling infection and preventing the development of 
chronic inflammatory diseases (88). Several preclinical therapeu-
tic approaches have been used to target NK cells for treating HCC. 
Therapies included induction of the activation of NK cells (with 
cytokines such as IL-2, IL-12, IL-15, IL-21, IFN-α, and IFN-γ) or 
performing adoptive transfers of activated NK cells. Type I IFNs 
has been shown to have antiviral, anti-fibrotic, and antitumor 
effects, likely due to their ability to stimulate NK cytolytic activ-
ity (37). IL-12 and IL-18 are also potent activators of NK cells 
that produce IFN-γ and TNF-α and have antiviral effects (95). 
Activation can also be achieved by blocking NK cell inhibitory 
receptors with monoclonal antibodies (mAb) (anti-NKG2A or 
anti-KIR), or by activating NK activating receptors to enhance 
NK cell ADCC against tumor cells.
Therapeutic approaches have been designed to use specific 
mAb to target co-inhibitory molecules (i.e., immune checkpoint 
inhibitors) that stop immune responses against tumor cells (96). 
Blocking these immune checkpoint inhibitors would release 
immune cells, including NK cells, from inhibitory mechanisms 
to restore their full immune activity. These immune checkpoint 
inhibitors are well described in the context of T cell exhaustion (97, 
98). They include cytotoxic T-lymphocyte antigen 4 (CTLA-4), 
programmed death 1 (PD-1), lymphocyte activation gene-3 
(LAG-3), T-cell immunoglobulin and mucin-domain-contain-
ing-3 (TIM-3), and B and T lymphocyte attenuator (BTLA). The 
expression of PD-1 and Tim-3 on liver NK cells from patients with 
HBV-related HCC is increased and also associated with immune 
cell exhaustion (99, 100). The promising results from clinical trials 
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using mAb against immune checkpoint inhibitors might also 
prove to be a likely therapeutic strategy for liver disease, especially 
in combination with drugs enhancing NK cell activation. Recent 
studies have shown that the expression of Tim-3 on peripheral 
CD56+ NK cells correlates with expression of serological markers 
of liver fibrosis in patients with advanced schistosomiasis (101). 
Blocking PD-1, CTLA-4, or Tim-3 pathway with mAbs could 
protect patients from fibrosis, cirrhosis, and HCC by restoring 
NK cell function. Several mAbs against PD-1 (ipilimumab, pem-
brolizumab, nivolumab), PD-L1 (atezolizumab, durvalumab), or 
CTLA-4 (tremelimumab/CP-675,206) are currently being tested 
in clinical trials against HCC.
NK  cell activation can also be achieved through blocking 
NK inhibitory receptors such as KIR, NKG2A/CD94, or TIGIT. 
Cancer cells or virus-infected cells upregulate the expression of 
MHC class I molecules (HLA in humans) as an immune escape 
mechanism in order to evade killing by NK and T cells. MHC I 
molecules in mice, and HLA molecules in humans, engage NK 
inhibitory receptors like Ly49 and NKG2A and KIR, respectively, 
to prevent NK  cell activation. Anti-NKG2A antibodies are 
already under investigation in several clinical trials alone, or in 
combination with other anticancer drugs (ibrutninb), mAb-like 
anti-EGFR (cetuximab), or anti-PD-L1 (duvalumab). New clini-
cal studies are in progress to test the antitumor effect of anti-KIR 
monoclonal antibody in combination with other drugs.
Taken together, the combination of NK  cell-based therapy 
with conventional therapies might become an efficient approach 
to cure or lessen the burden of liver cancers. More clinical trials 
are needed to evaluate the safety and efficiency of these combined 
approaches. In addition, NK cells play different roles depending 
on the developmental stage of a specific disease, emphasizing the 
importance of investigating the spatiotemporal role of NK cells in 
cancer and fibrosis. It is worth noting that most NK cell studies 
are done with peripheral and splenic NK cells, not with tissue-
resident NK cells. More investigations are required to determine 
the specific role of each NK cell subset, how these subsets con-
tribute to the development of tissue-specific disease, and the most 
effective therapeutic strategies for each disease.
SUMMARY AND CONCLUSiON
NK cells play crucial roles in regulation of chronic inflammatory 
diseases such as tissue fibrosis and cancer. Thus, the understand-
ing of NK-mediated immunoregulation would provide insight 
into designing therapeutics against viral infection and inflamma-
tory diseases. NK cells have a protective role in the development 
of liver fibrosis in the model of NAFLD development where they 
regulate the tight balance between liver inflammation and repair 
through macrophage polarization. Thus, the identification of 
NK cells as upstream regulators of macrophage function provides 
a new cellular target to modulate macrophage-mediated inflam-
mation in chronic liver diseases. Further exploration of the inter-
play between myeloid cells and NK cells may thus help identify 
key molecular regulators that can resolve chronic inflammation 
and restore immune homeostasis.
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